Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register allows you to search for protocol and results information on:
  • interventional clinical trials that are conducted in the European Union (EU) and the European Economic Area (EEA);
  • clinical trials conducted outside the EU / EEA that are linked to European paediatric-medicine development.
  • Learn   more about the EU Clinical Trials Register   including the source of the information and the legal basis.


    The EU Clinical Trials Register currently displays   42336   clinical trials with a EudraCT protocol, of which   6971   are clinical trials conducted with subjects less than 18 years old.
    The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).


    Phase 1 trials conducted solely in adults and that are not part of an agreed PIP are not public in the EU CTR (refer to European Guidance 2008/C 168/02   Art. 3 par. 2 and   Commission Guideline 2012/C 302/03,   Art. 5) .

    Clinical Trials marked as "Trial now transitioned" were transitioned to the Clinical Trial Regulation 536/2014 and can be further followed in the Clinical Trial Information System  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Download PDF

    Clinical Trial Results:
    The Effects of Isovolumetric and Isoeffective Infusions of Colloid Versus Crystalloid on Renal Blood Flow and Cardiac Output

    Summary
    EudraCT number
    2013-003260-32
    Trial protocol
    GB  
    Global end of trial date
    12 Nov 2015

    Results information
    Results version number
    v1(current)
    This version publication date
    14 Apr 2019
    First version publication date
    14 Apr 2019
    Other versions

    Trial information

    Close Top of page
    Trial identification
    Sponsor protocol code
    13090
    Additional study identifiers
    ISRCTN number
    -
    US NCT number
    -
    WHO universal trial number (UTN)
    -
    Sponsors
    Sponsor organisation name
    University of Nottingham
    Sponsor organisation address
    Jubilee Campus, Triumph Road, Nottingham, United Kingdom, NG8 1DH
    Public contact
    Shone, University of Nottingham, +44 1159315679, dileep.lobo@nottingham.ac.uk
    Scientific contact
    Angela Shone, Professor Dileep Lobo, +44 115 8467906, sponsor@nottingham.ac.uk
    Paediatric regulatory details
    Is trial part of an agreed paediatric investigation plan (PIP)
    No
    Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Results analysis stage
    Analysis stage
    Final
    Date of interim/final analysis
    12 Nov 2015
    Is this the analysis of the primary completion data?
    Yes
    Primary completion date
    12 Nov 2015
    Global end of trial reached?
    Yes
    Global end of trial date
    12 Nov 2015
    Was the trial ended prematurely?
    No
    General information about the trial
    Main objective of the trial
    The primary objective of this study is to determine the differential impact of isovolumetric and isoeffective infusions of crystalloid and gelatin on blood volume expansion - to test whether an infusion of a gelatin based colloid solution expands blood volume to a greater degree than an isovolumetric infusion of crystalloid, resulting in increased renal blood flow and perfusion, and cardiac output..
    Protection of trial subjects
    All interventions carried out on healthy volunteers in the presence of qualified doctors
    Background therapy
    -
    Evidence for comparator
    -
    Actual start date of recruitment
    02 Sep 2013
    Long term follow-up planned
    No
    Independent data monitoring committee (IDMC) involvement?
    No
    Population of trial subjects
    Number of subjects enrolled per country
    Country: Number of subjects enrolled
    United Kingdom: 12
    Worldwide total number of subjects
    12
    EEA total number of subjects
    12
    Number of subjects enrolled per age group
    In utero
    0
    Preterm newborn - gestational age < 37 wk
    0
    Newborns (0-27 days)
    0
    Infants and toddlers (28 days-23 months)
    0
    Children (2-11 years)
    0
    Adolescents (12-17 years)
    0
    Adults (18-64 years)
    12
    From 65 to 84 years
    0
    85 years and over
    0

    Subject disposition

    Close Top of page
    Recruitment
    Recruitment details
    Recruitment period 02.10.2014 to 12.11.2015

    Pre-assignment
    Screening details
    12 healthy, male volunteers, aged between 18 and 40 and weight between 65 and 80 kg. 2 participants later withdrew and were excluded from the analysis.

    Period 1
    Period 1 title
    Started first infusion
    Is this the baseline period?
    Yes
    Allocation method
    Randomised - controlled
    Blinding used
    Double blind
    Roles blinded
    Subject, Investigator, Monitor, Data analyst
    Blinding implementation details
    A nurse note involved in the study in charge of blinding the investigational products, program the automated infusion pump, set up and start the infusion and remove infusion equipment upon completion of administration. Infusion bags covered with opaque bags, in a manner making it not possible to recognize the number of bags being infused. The infusion lines covered to mask the yellowish colour of Gelatine. The data shown on the screen of the automated infusion pump masked to the investigator

    Arms
    Are arms mutually exclusive
    No

    Arm title
    Arm A : reference Sterofundin
    Arm description
    Infusion A: received 1500mls of crystalloid (Sterofundin ISO®)
    Arm type
    Active comparator

    Investigational medicinal product name
    Sterofundin ISO®
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Infusion
    Routes of administration
    Intravascular use
    Dosage and administration details
    1500mls of crystalloid (Sterofundin ISO®

    Arm title
    Arm B: 4% Gelaspan
    Arm description
    0.5 Litres of colloid (4% Gelaspan®)
    Arm type
    Experimental

    Investigational medicinal product name
    4% Gelaspan
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Infusion
    Routes of administration
    Intravenous use
    Dosage and administration details
    0.5 Litres of colloid (4% Gelaspan®)

    Arm title
    Arm C: collloid and crystalloid
    Arm description
    0.5 Litres of colloid plus 1 Litre of crystalloid (0.5 Litres 4% Gelaspan ® and 1 Litre of Sterofundin ISO ®)
    Arm type
    Experimental

    Investigational medicinal product name
    Sterofundin ISO®
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Infusion
    Routes of administration
    Intravascular use
    Dosage and administration details
    1500mls of crystalloid (Sterofundin ISO®

    Investigational medicinal product name
    4% Gelaspan
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Infusion
    Routes of administration
    Intravenous use
    Dosage and administration details
    0.5 Litres of colloid (4% Gelaspan®)

    Number of subjects in period 1
    Arm A : reference Sterofundin Arm B: 4% Gelaspan Arm C: collloid and crystalloid
    Started
    10
    10
    10
    Completed
    10
    10
    10
    Period 2
    Period 2 title
    Received all infusions
    Is this the baseline period?
    No
    Allocation method
    Randomised - controlled
    Blinding used
    Double blind
    Roles blinded
    Subject, Investigator, Monitor, Data analyst

    Arms
    Are arms mutually exclusive
    No

    Arm title
    Arm A : reference Sterofundin
    Arm description
    Infusion A: received 1500mls of crystalloid (Sterofundin ISO®)
    Arm type
    Active comparator

    Investigational medicinal product name
    Sterofundin ISO®
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Infusion
    Routes of administration
    Intravascular use
    Dosage and administration details
    1500mls of crystalloid (Sterofundin ISO®

    Arm title
    Arm B: 4% Gelaspan
    Arm description
    0.5 Litres of colloid (4% Gelaspan®)
    Arm type
    Experimental

    Investigational medicinal product name
    4% Gelaspan
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Infusion
    Routes of administration
    Intravenous use
    Dosage and administration details
    0.5 Litres of colloid (4% Gelaspan®)

    Arm title
    Arm C: collloid and crystalloid
    Arm description
    0.5 Litres of colloid plus 1 Litre of crystalloid (0.5 Litres 4% Gelaspan ® and 1 Litre of Sterofundin ISO ®)
    Arm type
    Experimental

    Investigational medicinal product name
    Sterofundin ISO®
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Infusion
    Routes of administration
    Intravascular use
    Dosage and administration details
    1500mls of crystalloid (Sterofundin ISO®

    Investigational medicinal product name
    4% Gelaspan
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Infusion
    Routes of administration
    Intravenous use
    Dosage and administration details
    0.5 Litres of colloid (4% Gelaspan®)

    Number of subjects in period 2
    Arm A : reference Sterofundin Arm B: 4% Gelaspan Arm C: collloid and crystalloid
    Started
    10
    10
    10
    Completed
    10
    10
    10

    Baseline characteristics

    Close Top of page
    Baseline characteristics reporting groups
    Reporting group title
    Started first infusion
    Reporting group description
    Number entered first infusion 10

    Reporting group values
    Started first infusion Total
    Number of subjects
    12 12
    Age categorical
    Units: Subjects
        In utero
    0 0
        Preterm newborn infants (gestational age < 37 wks)
    0 0
        Newborns (0-27 days)
    0 0
        Infants and toddlers (28 days-23 months)
    0 0
        Children (2-11 years)
    0 0
        Adolescents (12-17 years)
    0 0
        Adults (18-64 years)
    12 12
        From 65-84 years
    0 0
        85 years and over
    0 0
    Age continuous
    Age
    Units: years
        arithmetic mean (standard deviation)
    23.9 ± 2.8 -
    Gender categorical
    Units: Subjects
        Female
    0 0
        Male
    12 12
    Weight
    Units: kg
        arithmetic mean (standard deviation)
    74.5 ± 5.7 -
    Height
    Units: Metres
        arithmetic mean (standard deviation)
    1.81 ± 0.1 -
    Body Mass Index
    Units: kg/m squared
        arithmetic mean (standard deviation)
    22.7 ± 1.6 -
    Haemoglobin
    Units: g/L
        arithmetic mean (standard deviation)
    150.1 ± 7.6 -
    Haematocrit
    Units: Percent
        arithmetic mean (standard deviation)
    43.9 ± 1.9 -
    Sodium
    Units: mmol/L
        arithmetic mean (standard deviation)
    102.9 ± 1.3 -
    Serum bicarbonate
    Units: mmol/L
        arithmetic mean (standard deviation)
    28.2 ± 2.2 -
    Serum albumin
    Units: g/L
        arithmetic mean (standard deviation)
    41.2 ± 2.5 -
    Serum osmolality
    Units: mOsm/kg
        arithmetic mean (standard deviation)
    291 ± 2.5 -
    Creatinine
    Units: umol/L
        arithmetic mean (standard deviation)
    139.6 ± 37.9 -
    Calculated blood volume
    Units: Litres
        arithmetic mean (standard deviation)
    5.2 ± 1.6 -
    Subject analysis sets

    Subject analysis set title
    Infusion A versus Infusion B
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Differences between colloid versus crystalloid

    Subject analysis set title
    Infusion A versus Infusion C
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Difference between colloid versus crystalloid and colloid

    Subject analysis set title
    Infusion B versus Infusion C
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Difference between crystalloid and colloid/crystalloid

    Subject analysis sets values
    Infusion A versus Infusion B Infusion A versus Infusion C Infusion B versus Infusion C
    Number of subjects
    10
    10
    10
    Age categorical
    Units: Subjects
        In utero
        Preterm newborn infants (gestational age < 37 wks)
        Newborns (0-27 days)
        Infants and toddlers (28 days-23 months)
        Children (2-11 years)
        Adolescents (12-17 years)
        Adults (18-64 years)
    10
    10
    10
        From 65-84 years
        85 years and over
    Age continuous
    Age
    Units: years
        arithmetic mean (standard deviation)
    23.9 ± 2.8
    23.9 ± 2.8
    23.9 ± 2.8
    Gender categorical
    Units: Subjects
        Female
    0
    0
    0
        Male
    10
    10
    10
    Weight
    Units: kg
        arithmetic mean (standard deviation)
    ±
    ±
    ±
    Height
    Units: Metres
        arithmetic mean (standard deviation)
    ±
    ±
    ±
    Body Mass Index
    Units: kg/m squared
        arithmetic mean (standard deviation)
    ±
    ±
    ±
    Haemoglobin
    Units: g/L
        arithmetic mean (standard deviation)
    ±
    ±
    ±
    Haematocrit
    Units: Percent
        arithmetic mean (standard deviation)
    ±
    ±
    ±
    Sodium
    Units: mmol/L
        arithmetic mean (standard deviation)
    ±
    ±
    ±
    Serum bicarbonate
    Units: mmol/L
        arithmetic mean (standard deviation)
    ±
    ±
    ±
    Serum albumin
    Units: g/L
        arithmetic mean (standard deviation)
    ±
    ±
    ±
    Serum osmolality
    Units: mOsm/kg
        arithmetic mean (standard deviation)
    ±
    ±
    ±
    Creatinine
    Units: umol/L
        arithmetic mean (standard deviation)
    ±
    ±
    ±
    Calculated blood volume
    Units: Litres
        arithmetic mean (standard deviation)
    ±
    ±
    ±

    End points

    Close Top of page
    End points reporting groups
    Reporting group title
    Arm A : reference Sterofundin
    Reporting group description
    Infusion A: received 1500mls of crystalloid (Sterofundin ISO®)

    Reporting group title
    Arm B: 4% Gelaspan
    Reporting group description
    0.5 Litres of colloid (4% Gelaspan®)

    Reporting group title
    Arm C: collloid and crystalloid
    Reporting group description
    0.5 Litres of colloid plus 1 Litre of crystalloid (0.5 Litres 4% Gelaspan ® and 1 Litre of Sterofundin ISO ®)
    Reporting group title
    Arm A : reference Sterofundin
    Reporting group description
    Infusion A: received 1500mls of crystalloid (Sterofundin ISO®)

    Reporting group title
    Arm B: 4% Gelaspan
    Reporting group description
    0.5 Litres of colloid (4% Gelaspan®)

    Reporting group title
    Arm C: collloid and crystalloid
    Reporting group description
    0.5 Litres of colloid plus 1 Litre of crystalloid (0.5 Litres 4% Gelaspan ® and 1 Litre of Sterofundin ISO ®)

    Subject analysis set title
    Infusion A versus Infusion B
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Differences between colloid versus crystalloid

    Subject analysis set title
    Infusion A versus Infusion C
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Difference between colloid versus crystalloid and colloid

    Subject analysis set title
    Infusion B versus Infusion C
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Difference between crystalloid and colloid/crystalloid

    Primary: Change in blood volume

    Close Top of page
    End point title
    Change in blood volume
    End point description
    Change in blood volume over time. The end point values for each time point have been given in the attached table.
    End point type
    Primary
    End point timeframe
    Blood sampled at baseline and times 30, 60, 90, 120, 180 and 240 minutes
    End point values
    Arm A : reference Sterofundin Arm B: 4% Gelaspan Arm C: collloid and crystalloid Infusion A versus Infusion B Infusion A versus Infusion C Infusion B versus Infusion C
    Number of subjects analysed
    10
    10
    10
    10
    10
    10
    Units: Litres
    10
    10
    10
    10
    10
    10
    Attachments
    Blood volume
    Statistical analysis title
    Change in blood volume
    Statistical analysis description
    For all secondary endpoints the statistical analyses are presented in the attached tables.
    Comparison groups
    Infusion A versus Infusion B v Infusion A versus Infusion C v Infusion B versus Infusion C
    Number of subjects included in analysis
    30
    Analysis specification
    Pre-specified
    Analysis type
    non-inferiority [1]
    P-value
    > 0.05 [2]
    Method
    ANOVA
    Confidence interval
    Notes
    [1] - Repeated measures ANOVA Change in blood volume (A v B, B v C, A v C)
    [2] - P > 0.05 for all comparisons.

    Secondary: Change in weight

    Close Top of page
    End point title
    Change in weight
    End point description
    Weight change monitored at 0, 90, 120, 180 and 240 minutes after the start of the infusion The end point values for each time point have been given in the attached table.
    End point type
    Secondary
    End point timeframe
    0, 90, 120, 180, and 240 mins
    End point values
    Arm A : reference Sterofundin Arm B: 4% Gelaspan Arm C: collloid and crystalloid Infusion A versus Infusion B Infusion A versus Infusion C Infusion B versus Infusion C
    Number of subjects analysed
    10
    10
    10
    10
    10
    10
    Units: Kilograms
    10
    10
    10
    10
    10
    10
    Attachments
    Change in weight
    No statistical analyses for this end point

    Secondary: Change in haematocrit %

    Close Top of page
    End point title
    Change in haematocrit %
    End point description
    The end point values for each time point have been given in the attached table.
    End point type
    Secondary
    End point timeframe
    Blood will be sampled at 60, 90, 120, 180 and 240 minutes after the start of the infusion
    End point values
    Infusion A versus Infusion B Infusion A versus Infusion C Infusion B versus Infusion C
    Number of subjects analysed
    10
    10
    10
    Units: percentage
    10
    10
    10
    Attachments
    Change in haematocrit
    No statistical analyses for this end point

    Secondary: Change in albumin %

    Close Top of page
    End point title
    Change in albumin %
    End point description
    The end point values for each time point have been given in the attached table.
    End point type
    Secondary
    End point timeframe
    Blood sampled at baseline and times 0, 30, 60, 90, 120, 180 and 240 minutes
    End point values
    Arm A : reference Sterofundin Arm B: 4% Gelaspan Arm C: collloid and crystalloid Infusion A versus Infusion B Infusion A versus Infusion C Infusion B versus Infusion C
    Number of subjects analysed
    10
    10
    10
    10
    10
    10
    Units: percentage
    10
    10
    10
    10
    10
    10
    No statistical analyses for this end point

    Secondary: Serum sodium mmol/l

    Close Top of page
    End point title
    Serum sodium mmol/l
    End point description
    The end point values for each time point have been given in the attached table.
    End point type
    Secondary
    End point timeframe
    Blood sampled at baseline and times 30, 60, 90, 120, 180 and 240 minutes
    End point values
    Arm A : reference Sterofundin Arm B: 4% Gelaspan Arm C: collloid and crystalloid Infusion A versus Infusion B Infusion A versus Infusion C Infusion B versus Infusion C
    Number of subjects analysed
    10
    10
    10
    10
    10
    10
    Units: mmol/l
    10
    10
    10
    10
    10
    10
    Attachments
    Serum Sodium
    No statistical analyses for this end point

    Secondary: Aortic flow (ml/s)

    Close Top of page
    End point title
    Aortic flow (ml/s)
    End point description
    The end point values for each time point have been given in the attached table. Comparisons between groups using un-paired t-test, comparison over time using paired t-test.
    End point type
    Secondary
    End point timeframe
    MRI at -15, 7, 26, 54 and 83 minutes
    End point values
    Arm A : reference Sterofundin Arm B: 4% Gelaspan Arm C: collloid and crystalloid Infusion A versus Infusion B Infusion A versus Infusion C Infusion B versus Infusion C
    Number of subjects analysed
    10
    10
    10
    10
    10
    10
    Units: ml/s
    10
    10
    10
    10
    10
    10
    Attachments
    Aortic flow
    No statistical analyses for this end point

    Secondary: Serum chloride mmol/l

    Close Top of page
    End point title
    Serum chloride mmol/l
    End point description
    The end point values for each time point have been given in the attached table.
    End point type
    Secondary
    End point timeframe
    Blood sampled at baseline and times 30, 60, 90, 120, 180 and 240 minutes
    End point values
    Arm A : reference Sterofundin Arm B: 4% Gelaspan Arm C: collloid and crystalloid Infusion A versus Infusion B Infusion A versus Infusion C Infusion B versus Infusion C
    Number of subjects analysed
    10
    10
    10
    10
    10
    10
    Units: mmol/l
    10
    10
    10
    10
    10
    10
    Attachments
    Serum Chloride
    No statistical analyses for this end point

    Secondary: Renal volume (ml)

    Close Top of page
    End point title
    Renal volume (ml)
    End point description
    The end point values for each time point have been given in the attached table. Comparisons between groups using un-paired t-test, comparison over time using paired t-test.
    End point type
    Secondary
    End point timeframe
    MRI at -5, 10, 38, 57 and 90 min
    End point values
    Arm A : reference Sterofundin Arm B: 4% Gelaspan Arm C: collloid and crystalloid Infusion A versus Infusion B Infusion A versus Infusion C Infusion B versus Infusion C
    Number of subjects analysed
    10
    10
    10
    10
    10
    10
    Units: ml/s
    10
    10
    10
    10
    10
    10
    Attachments
    Renal volume
    No statistical analyses for this end point

    Secondary: Strong ion differences

    Close Top of page
    End point title
    Strong ion differences
    End point description
    The end point values for each time point have been given in the attached table.
    End point type
    Secondary
    End point timeframe
    Blood sampled at baseline and times 30, 60, 90, 120, 180 and 240 minutes
    End point values
    Arm A : reference Sterofundin Arm B: 4% Gelaspan Arm C: collloid and crystalloid Infusion A versus Infusion B Infusion A versus Infusion C Infusion B versus Infusion C
    Number of subjects analysed
    10
    10
    10
    10
    10
    10
    Units: mmol/l
    10
    10
    10
    10
    10
    10
    Attachments
    Strong io difference
    No statistical analyses for this end point

    Secondary: Renal artery blood flow

    Close Top of page
    End point title
    Renal artery blood flow
    End point description
    The end point values for each time point have been given in the attached table. Comparisons between groups using un-paired t-test, comparison over time using paired t-test.
    End point type
    Secondary
    End point timeframe
    MRI at -15, 15, 43, 62 and 95 min
    End point values
    Arm A : reference Sterofundin Arm B: 4% Gelaspan Arm C: collloid and crystalloid Infusion A versus Infusion B Infusion A versus Infusion C Infusion B versus Infusion C
    Number of subjects analysed
    10
    10
    10
    10
    10
    10
    Units: ml/s
    10
    10
    10
    10
    10
    10
    Attachments
    Renal flow
    No statistical analyses for this end point

    Adverse events

    Close Top of page
    Adverse events information
    Timeframe for reporting adverse events
    Throughout trial
    Assessment type
    Systematic
    Dictionary used for adverse event reporting
    Dictionary name
    MedDRA
    Dictionary version
    1.0
    Reporting groups
    Reporting group title
    All groups
    Reporting group description
    -

    Serious adverse events
    All groups
    Total subjects affected by serious adverse events
         subjects affected / exposed
    0 / 10 (0.00%)
         number of deaths (all causes)
    0
         number of deaths resulting from adverse events
    0
    Frequency threshold for reporting non-serious adverse events: 1%
    Non-serious adverse events
    All groups
    Total subjects affected by non serious adverse events
         subjects affected / exposed
    2 / 10 (20.00%)
    Cardiac disorders
    Tachycardia
         subjects affected / exposed
    2 / 10 (20.00%)
         occurrences all number
    2
    General disorders and administration site conditions
    Excessive sweating
         subjects affected / exposed
    1 / 10 (10.00%)
         occurrences all number
    1

    More information

    Close Top of page

    Substantial protocol amendments (globally)

    Were there any global substantial amendments to the protocol? No

    Interruptions (globally)

    Were there any global interruptions to the trial? No

    Limitations and caveats

    Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.
    None reported
    For support, visit the EMA Service Desk , log in using your EMA account and open a ticket specifying "EU CTR" in your request.
    If you do not have an account, please visit the EMA Account management page page click on "Create an EMA account" and follow the instructions.
    The status of studies in GB is no longer updated from 1.1.2021
    For the UK, as from 1.1.2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI
    EU Clinical Trials Register Service Desk: https://servicedesk.ema.europa.eu
    European Medicines Agency © 1995-2022 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    Legal notice
    EMA HMA